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Luminescence imaging–based guidance technologies are 
increasingly gaining interest within surgical and radiologic 
disciplines. Their promise to help visualize molecular fea-
tures of disease in real time and with microscopic detail 
is considered desirable. Integrating luminescence imaging 
with three-dimensional radiologic- and/or nuclear medi-
cine–based preinterventional imaging may overcome lim-
itations such as the limited tissue penetration of lumines-
cence signals. At the same time, the beneficial features 
of luminescence imaging may be used to complement the 
routinely used radiologic- and nuclear medicine–based 
modalities. To fully exploit this integrated concept, and 
to relate the largely experimental luminesce-based guid-
ance approaches into perspective with routine imaging 
approaches, it is essential to understand the advantages 
and limitations of this relatively new modality. By provid-
ing an overview of the available luminescence technologies 
and the various clinically evaluated exogenous luminescent 
tracers (fluorescent, hybrid, and theranostic tracers), this 
review attempts to place luminescence-based interven-
tional molecular imaging technologies into perspective to 
the available radiologic- and/or nuclear medicine–based 
imaging technologies. At the same time, the transition 
from anatomic to physiologic and even molecular inter-
ventional luminescence imaging is illustrated.
q RSNA, 2015
Online supplemental material is available for this article.
1 From the Department of Radiology, Interventional Molecular 
Imaging Laboratory and Section of Interventional Radiology 
(F.W.B.v.L., A.R.v.E.), and Department of Gastroenterology 
(J.C.H.H.), Leiden University Medical Center, Albinusdreef 2, 
PO Box 9600, 2300 RC Leiden, the Netherlands. Received 
November 24, 2013; revision requested January 15, 
2014; revision received June 18; accepted August 11; 
final version accepted October 10. Supported in part by a 
Dutch Cancer Society translational research award (grant 
PGF 2009-4344) and an NWO-STW-VIDI grant (STW BGT 
11272). Address correspondence to F.W.B.v.L. (e-mail: 
f.w.b.van_leeuwen@lumc.nl).
q RSNA, 2015
Note: This copy is for your personal non-commercial use only. To order presentation-ready 
copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights.
Radiology: Volume 276: Number 1—July 2015 n radiology.rsna.org 13
REVIEW: Luminescence-based Approaches in  Interventional Molecular  Imaging van Leeuwen et al
Imaging technologies are increas-ingly being used to provide guid-ance prior to and during interven-
tions (1,2). While the use of anatomic 
imaging information during radiologic 
or surgical interventions is a common 
practice, it is desirable to obtain a 
real-time readout of the target lesion, 
preferably one that includes specific 
molecular parameters. This feature 
may be used to ensure a more effec-
tive treatment, while minimizing the 
amount of healthy tissue that is dam-
aged. In the clinic, luminescence imag-
ing refers to the visualization of lesions 
by using either light emitted from tis-
sue (so-called tissue autofluorescence 
[a fluorescent signal produced by 
Essentials
 n A basic understanding of the 
technique of luminescence-based 
imaging approaches is required 
before radiologists, nuclear medi-
cine physicians, and surgeons 
can incorporate this approach in 
their spectrum of imaging 
modalities.
 n Preinterventional staging with 
established total body and/or 
cross-sectional imaging technol-
ogies is mandatory to allow mini-
mally invasive luminescence-
based guidance to deeper-lying 
lesions or to lesions with an 
unknown location.
 n The beneficial features of lumi-
nescence imaging may be used to 
complement more established 
radiologic- and nuclear medi-
cine–based imaging approaches.
 n Despite the theoretical advan-
tages of near-infrared fluores-
cence imaging, luminescent 
tracers that emit within the 
visual spectrum have been most 
widely applied in clinical trials.
 n Various clinical trials have illus-
trated that luminescent tracers 
may ease lesion identification for, 
for example, surgeons, but for 
most of these procedures the 
effect on the clinical outcome still 
has to be proven.
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endogenous molecules, eg, hemoglo-
bin]) or a particular luminescent tracer 
(exogenous contrast agent [either fluo-
rescent, hybrid, or Cerenkov]). Clin-
ically, luminescence-based imaging 
was first introduced in 1924 (3) with 
the observation of a “red” fluorescent 
emission coming from hematoporphy-
rin illuminated with a Woods lamp. In 
the 1940s, the fluorescent dye fluores-
cein was shown to allow delineation of 
brain tumors (4). In the past decade, 
the development of light-sensitive 
(near-infrared) fluorescence cameras 
has initiated a renewed interest in 
these optical technologies. The main 
driving force behind this revival is the 
theoretical potential to improve real-
time (microscopic) identification and 
delineation of lesions that cannot be 
accurately defined otherwise, for ex-
ample, by palpation and/or the naked 
human eye. However, before radiolo-
gists, nuclear medicine physicians, and 
surgeons can incorporate such lumi-
nescence-based imaging approaches in 
their spectrum of imaging modalities, 
they will have to acquire a basic under-
standing of this modality.
Since luminescence-based imaging 
is limited by its signal penetration (, 
1 cm), the utility of this technology is 
driven by the accessibility of the tissue 
with a camera. This means the tech-
nology can only be used to identify su-
perficial lesions with a known origin, 
for example, colorectal neoplasia (5). 
The use of luminescence-based imag-
ing for deeper-lying lesions or lesions 
with an unknown location still requires 
the simultaneous or complementary 
use of established total body and/or 
cross-sectional imaging technologies 
such as ultrasonography (US), x-ray-
based technologies, computed tomog-
raphy (CT), magnetic resonance (MR) 
imaging, single photon emission CT 
(SPECT), or positron emission to-
mography (PET) (Fig 1). These well-
established radiologic and/or nuclear 
medicine modalities not only provide 
a means of “preselecting” patients who 
may benefit from luminescence imag-
ing, they may also serve as a three-
dimensional road map or even provide 
a basis for mixed-reality navigation, 
followed by local luminescence imag-
ing (6–8). Ultimately, patients may 
benefit from an integrated approach 
wherein routine clinical imaging tools 
are complemented with luminescence 
imaging (9). In this concept, the latter 
makes it possible to zoom in on mo-
lecular features of disease spread (10). 
When such integration is achieved, a 
so-called combined pre-intervention 
and interventional imaging paradigm 
is created.
Two main principles describe the 
essence of this paradigm: (a) use of 
preintervention (molecular) imaging 
data to guide interventional lumines-
cence imaging and (b) use of interven-
tional luminescence-based imaging to 
help obtain more detailed (molecular) 
information from the target lesion(s). 
These two forms of complementary 
imaging may be achieved by using ei-
ther two separate but complementary 
tracers, of which one is luminescent in 
nature, or by using hybrid tracers that 
can be detected by using multiple dif-
ferent imaging modalities.
This review attempts to place the 
role of clinically applied luminescent 
tracers and luminescence-based op-
tical imaging technologies into per-
spective. Only exogenous tracers 
(fluorescent, hybrid, and theranos-
tic) that have been described in clini-
cal trials are reviewed (Tables 1–3). 
Of these concepts, the underlying 
physics, shortcomings, overlap with 
findings with use of radiologic and/or 
nuclear medicine modalities, and the 
potential added value of luminescence-
based optical imaging technologies are 
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Figure 1
Figure 1: Schematic illustration of the different imaging technologies available for interventional guidance. Modalities are sub-
divided into anatomic, physiologic, and molecular groups. Note that molecular modalities may also be used to visualize physiologic 
parameters. To place luminescence imaging in context with the other available imaging technologies, a separation is made between 
true “in-depth” modalities and superficial technologies such as US (, 10 cm) and luminescence imaging (, 1 cm). Images are 
purely meant for illustration. The images on the left depict imaging the liver in a preinterventional (diagnostic imaging) setting. 
Images on the right show a range of applications that are mainly used for guidance during the intervention in the intraoperative 
setting. The anatomic image was made by using the visual body software package (Human Anatomy Atlas, version 3.0.1; Argosy, 
Newton Upper Falls, Mass). CE = contrast enhanced.
discussed. A particular focus is placed 
on the transition from anatomic imag-
ing to physiologic and even molecular 
imaging approaches in the field of on-
cologic interventions.
Basic Principle of Luminescence-based 
Imaging
Essentially, luminescence-based im-
aging focuses on the detection of 
light that is emitted from a diseased 
area. The emission spectrum of lu-
minescent tracers intended for med-
ical use encompasses ultraviolet light 
(, 400 nm), visible light (400–650 nm), 
far-red light (650–780 nm), and the in-
ternational union of pure and applied 
chemistry defined near-infrared range 
of 780–2000 nm (11). This review dis-
cusses the use of two types of lumines-
cent signals, namely fluorescence (used 
in fluorescent, hybrid, and theranostic 
tracers) and Cerenkov luminescence. 
The physical principles and limitations 
of these technologies are briefly intro-
duced below.
Fluorescence
The basic principle of fluorescence im-
aging is that dyes convert light shined 
onto them (excitation light) into light 
of a longer wavelength (emission light); 
to get a light signal from a fluorescent 
tracer, light needs to go in first. For 
that reason, detection of fluorescent 
signals requires a modality comprising 
both an excitation light source and a 
light-sensitive camera that can detect 
the emitted light.
When the light spectrum used for 
excitation falls within the excitation 
spectrum of a specific fluorescent dye, 
the dye is converted to its excited state 
(Fig 2, A). When this dye decays back 
to its stable ground-state, light with 
a lower energy is emitted (Fig 2, B). 
Both the excitation and emission 
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Table 1
Clinically Evaluated Fluorescent Tracers
Fluorescent Tracer
Regulatory  
Status (only FDA  











 Fluorescein (NDA)022186 &  
 (NDA)021980
Angiography of, for example, the eye (reference  
 standard) and epicerebral microcirculation  
 (n = 5) (42,107)
488/515 92 (108) 8 3 104 (108)
Ureter visualization (n = 12) (54)
Lymphangiography (n = .1000) (56)
String test for gastrointestinal hemorrhage (n = 32)  
 (109)
Confocal endomicroscopy of colon (n = 42) (71)
 FITC-dextran 150 000 Lymphangiography (n = 39) (57) 488/515 92 (108) 8 3 104 (108)
 Cresyl violet Confocal endomicroscopy of colon (n = 36) (72) 591/628 54 (110) —
 Acrilflavine hydrochloride Confocal endomicroscopy of colon (n = 8) (70) 416/514 — —
 Methylene blue With FDA warning Ureter visualization (n = 12) (55) 670/680 4 (111) 9 3 104 (111)
Parathyroid adenoma imaging (n = 12) (49)
Melanoma delineation via fluorescence polarization  
 imaging (ex vivo, n = 6) (112)
 Omocyanine Breast cancer detection (n = 11) (46) 761/781 17 (46) —
 ICG (ANDA)040811 &  
 (NDA)011525
Perfusion of, for example, kidney (n = 94) or free-flap  
 reconstruction (n = 20) (40,113)
780/820 3.3 (41) 4 3 105 (114)
Angiography of, for example, the eye (1000 eyes) (115)
Lymphangiography (n = 22) (116)
Uretereral stenosis (n = 7) (117)
Tumor visualization of, for example, HCC or colorectal  
 liver metastasis (n = 49) (104)
Cholangiography (n = 13) (50)
Hepatic segmentectomy(118)
Confocal mini-laparoscopy of liver (n = 22) (29)
Sentinel node mapping (n = 18) (58)
Targeted
 Folate-FITC Folate receptor a+ ovarian carcinoma (n = 10) (75) 488/515 92 (108) 8 3 104 (108)
 CEA-mAB-FITC Colorectal carcinoma imaging (n = 1; ex vivo, n = 5)  
 (119)
488/515 92 (108) 8 3 104 (108)
 VRPMLQ-FITC Colonic dysplasia (n = 26) (79) 488/515 92 (108) 8 3 104 (108)
 ASYNYDA-GGGSK-FITC Esophageal neoplasia (n = 25) (80) 488/515 92 (108) 8 3 104 (108)
 GE137 c-MET-overexpressing colon lesions (n = 15) (5) 650/670 28 2 3 105 (120)
 GGT-HMRG g-GGT (ex vivo) (81) 501/524 81 (121) 6 3 104 (121)
 anti-EGFR mAB Alexa  
 Fluor 488
Colorectal neoplasia (n = 37) (77) 488/520 92 7 3 104
 MG7-AF488 Gastric cancer (ex vivo, 46 samples) (122) 488/520 92 7 3 104
 CW800-bevacizumab VEGF (breast cancer, n = 20 [no in vivo data  
 published yet]) (123)
783/801 12 (124) 2 3 105 (125)
Note.—FDA = Food and Drug Administration, lex max = maximum peak excitation wavelength, lem max = maximum peak emission wavelength, FITC = fluorescein isothiocyanate, ICG = indocyanine green, 
HCC = hepatocellular carcinoma, CEA = carcinoembryonic antigen, mAB = monoclonal antibody, GGT = glutamyltranspeptidase, EGFR = epidermal growth factor receptor, VEGF = vascular endothelial 
growth factor.
* The number of patients is from representative studies; the clinical use of the compounds is not necessarily limited to these studies.
spectra dictating this process have a 
range and a maximum peak (maxi-
mum peak excitation wavelength, or 
lex max, and maximum peak emission 
wavelength, or lem max) that is charac-
teristic for individual fluorescent dyes 
(Tables 1–3), meaning camera set-
tings have to be tailored toward these 
spectra depending on the fluorescent 
tracer used. For accurate detection 
of the signal, the eye or camera also 
needs to have a good sensitivity in the 
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Status (only FDA  







Molar Absorbance  
Coefficient  
(l mol21 cm21)
Doxycycline (ANDA)062569 &  
  (ANDA)091406  
(intravenous injection)
Osteonecrosis (n = 2) (95) (n = 15) (126) 345/570 5 (127) 1 3 104 (127)
Tetracyclin (ANDA)061837  
 (oral administration)
Osteoid osteoma (n = 9) (128) 357/570 0.2 (127) 1 3 104 (127)
Nonmelanoma delineation via fluorescence  
 polarization imaging (ex vivo, n = 32) (129)
Melanoma delineation via fluorescence polarization  
 imaging (ex vivo, n = 6) (112)
Demeclocycline Nonmelanoma delineation via fluorescence  
 polarization imaging (ex vivo, n = 54) (129)
367/585 4 (127) 1 3 104 (127)
5-ALA, HAL, MAL PpIX-based PDD of a variety of malignancies  
 (eg, brain, bladder and oral cancer)(97)
406/632 1.1 (130) 3 3 104 (131)
Hypericin Wide application in PDD of, for example, bladder  
 cancer(103)
595/600 2 4 3 104 (132)
mTHPC Wide application in PDD of, for example, brain  
 tumors(102)
417/6502653 8.9 (133) 2 3 105 (417 nm  
 [134]) and 3 3 104  
(650 nm [133])
Note.—FDA = Food and Drug Administration, lex max = maximum peak excitation wavelength, lem max = maximum peak emission wavelength, PpIX = protoporphyrin IX, 5-ALA = 5-aminolevulinate, MAL 
= methyl aminolevulinate, HAL = hexyl aminolevulinate, mTHPC = meta-tetrahydroxyphenylchlorin.
* The number of patients mentioned is from representative studies; the clinical use of the compounds is not necessarily limited to these studies.
Table 2
Hybrid Tracers Used for Image-guided Surgery
Hybrid Tracer
Regulatory  
Status (only FDA  







Molar Absorbance  
Coefficient  
(l mol21 cm21)
Ionidated methylene blue  
(125I,131I, or 123I)
Sentinel node mapping (n = 12) (88) 670/680 4 (111) 9 3 104 (111)
Parathyroid imaging (n = 5) (86)
Melanoma metastases (n = 6) (87)
131I-diiodofluorescein Brain tumors (n = 12) (82) 488/515 92 (108) 8 3 104 (108)
ICG-99mTc-nanocolloid Sentinel node identification (n = 11) (13) 780/820 3.3 (44) 4 3 105 (114)
18F-FDG (NDA)021870 Lymph node imaging (n = 4) (32) ,200/- — —
131I (NDA)010929 Thyroid (n = 1) (31) ,200/- — —
Note.—FDA = Food and Drug Administration, lex max = maximum peak excitation wavelength, lem max = maximum peak emission wavelength, 
125I = iodine 125, 131I = iodine 131, 123I = iodine 123, 
99mTc = technetium Tc 99m, 18F = fluoride18, FDG = fluorodeoxyglucose.
* The number of patients mentioned is from representative studies; the clinical use of the compounds is not necessarily limited to these studies.
range of the emitted light. To improve 
the specificity of cameras for emis-
sion light detection, often band-pass 
filters are used that block background 
signals such as reflected excitation 
light, autofluorescence, and ambient 
light. This latter technique can also 
be used to differentiate between vari-
ous fluorescent signals (exemplified in 
Fig 3, D).
The signal intensity (photon flux) 
varies between fluorescent dyes and 
depends on: (a) the intensity of the ex-
citation light (increasing the intensity 
of the light source will increase the 
amount of emitted photons); (b) the 
efficiency of light absorption (the ab-
sorption coefficient [´] is generally de-
termined at the absorption maximum) 
(Tables 1–3); and (c) the quantum yield 
(the number of emitted photons per 
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Figure 2
Figure 2: Schematic presentation of the different features influencing emission of luminescent signals in tissue. A, Excitation of a luminescent dye (only applica-
ble for fluorescence). Penetration of excitation light is limited by reflection, scattering, and the efficacy of light absorption, leading to the excitation of the dye and 
subsequent relaxation. B, Emission of a luminescent signal (applicable to both fluorescence and Cerenkov). In addition to the effects mentioned in, A, detection of 
emitted light is further limited by presence of autofluorescence and ambient light. C, Due to the features described in, A and B, luminescence imaging is a superficial 
technology, whereby the resolution is optimal at a minimal depth. This is illustrated by the clarity with which the blue signal is presented. Anatomic images were made 
by using the visual body software package (Human Anatomy Atlas, version 3.0.1; Argosy). 2D = Two-dimensional, 3D = three-dimensional, l
ex
 = peak excitation 
wavelength, l
em
 = peak emission wavelength.
absorbed photon with a maximum of 
100%; Tables 1–3) (1).
Cerenkov Luminescence
Cerenkov luminescence is a “sponta-
neous light emission” generated by a 
b particle traveling through a medium. 
The wide range of commercially avail-
able PET tracers (b+ particle emitters) 
and therapeutic isotopes (b2 particle 
emitters) can potentially be used for 
Cerenkov luminescence imaging. For 
all b particle–emitting isotopes, the 
Cerenkov emission signal is identical, 
showing a maximum peak emission 
wavelength below 200 nm, accom-
panied by an emission tail extending 
into the near-infrared region. As a 
result, other than with fluorescence 
imaging, where each type of fluores-
cent dye requires specific camera filter 
settings, only one type of Cerenkov lu-
minescence camera system is required 
to detect the Cerenkov luminescence 
signal from various b particle–emitting 
tracers.
The photon flux of Cerenkov lumi-
nescence depends on the amount of the 
radiotracer administered; the radioac-
tive decay of the isotopes will reduce 
the luminescence signal intensity with 
time. The efficacy of medium polariza-
tion and subsequent light conversion 
process increases with increasing en-
ergy of the b particle (1).
Limiting Factors in Luminescence 
Imaging
Identical to the radionuclide emission 
signal, luminescence signals are emit-
ted in three dimensions. However, 
with the currently available clinical 
luminescence camera systems, the lu-
minescent signal can only be detect-
ed in two dimensions, geometrically 
limiting the sensitivity of detection. 
Other factors that may influence the 
signal detectability are: (a) light ab-
sorption by the tissue (occurring dur-
ing both excitation and emission); (b) 
light scattering (occurring during both 
excitation and emission); (c) tissue 
autofluorescence; and (d) background 
signals caused by reflection and am-
bient light (Fig 2, A). While fluores-
cence imaging suffers from the limi-
tations related to both the excitation 
and emission light, for Cerenkov lumi-
nescence imaging, only those related 
to the emitted light apply. That said, 
the limited signal intensity (orders of 
magnitude lower than those obtained 
during fluorescence imaging) and the 
broad emission profile of Cerenkov 
emission means that this technique 
will be influenced more by the pres-
ence of ambient light and requires 
longer acquisition times (1).
The influence of signal attenuation 
(and autofluorescence) is strongest 
at lower wavelengths. Therefore, at 
identical conditions, and assuming an 
identical photon flux, the penetration 
depth of a fluorescent dye emitting in 
the visible spectrum (eg, fluorescein) 
is more limited compared with that 
of a dye emitting in the near-infrared 
window (eg, ICG) (12). However, de-
spite the excellent results obtained in 
phantom setups, clinical studies indi-
cate that even near-infrared dyes such 
as ICG only add value in superficial 
imaging applications; lesions more 
than 1 cm deep might be missed due 
to faint and diffuse tissue staining (Fig 
2, C) (13). Efforts aiming at improv-
ing the effective depth at which lumi-
nescent tracers can be detected are 
mainly based on using complementary 
feedback provided via radioisotopes 
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Figure 3
Figure 3: Achieved technologic advances to improve luminescence imaging. A, The availability of white light information helps place the luminescence findings in 
anatomic context. The image shows fluorescence imaging of the hybrid tracer ICG-99mTc-nancolloid resulting in the visualization of a prostate-draining sentinel node 
(fluorescence in blue). The insert shows the same image without the anatomic background detail. B, The pseudo-color used to depict the near-infrared fluorescence 
signal in a prostate-draining sentinel node (ICG-99mTc-nanocolloid) may affect the identification during surgery. Although the blue contrast (main image) is clear, the 
more contrast with the background is obtained the fluorescent signal is displayed in green (insert). C, Depiction of the fluorescence intensity of ICG in heat-map color 
coding can help depict vascular malformations in the brain. The insert shows corresponding three-dimensional rendering of a CT angiogram of the same lesion. 
(Reprinted, with permission, from reference 26.) D, Multiplexing allows sequential visualization of two different luminescent emissions that depict complementary 
features: i) a prostate-draining sentinel node containing ICG-99mTc-nanocolloid (fluorescence in blue; near-infrared settings) and ii) lymphatic vessels draining from the 
prostate to the sentinel node (fluorescence in yellow/green; fluorescein settings). Dotted arrow = the sentinel node, arrows = draining lymphatic ducts. E, Fiber-based 
microscopic fluorescence imaging can be used to visualize fluorescein accumulation at a cellular level in the lumen of the colon. The fluorescence image is shown as 
a black-and-white image; fluorescein is displayed in white. (Reprinted, with permission, from reference 35.)
(hybrid or Cerenkov tracers) and an 
alternative technology, namely photo-
acoustics, whereby the absorbance of 
light in a molecule leads to an excita-
tion that can be detected with a US 
probe (14).
Contrast Agent Sensitivity of 
Luminescence Imaging Modalities 
Relative to Radiologic- and Nuclear 
Medicine–based Imaging Modalities
For interventional guidance, a variety 
of modalities is available, all of which 
have their own strengths and weak-
nesses. In particular, the contrast 
agent sensitivity, meaning the amount 
of moles of contrast agent required for 
detection, and thus the ability to depict 
molecular features of disease, strongly 
differs between these modalities (15).
Of the routinely used radiologic 
modalities, US has the highest con-
trast agent sensitivity (1029 to 10212 
mol), but here the contrast agent 
mainly remains confined to the vas-
cular system, limiting the use of this 
modality for molecular imaging pur-
poses. The maximal contrast agent 
sensitivity of CT is approximately 
1023 mol, for MR imaging it is 1026 
mol (pharmacological range). These 
low sensitivities restrict their ability 
to distinguish between biomarker ex-
pression levels. On the other hand, 
at nuclear medicine, PET and SPECT 
scanners can effectively depict tracer 
quantities of contrast material (10210 
to 10215 mol), allowing visualization of 
the molecular fingerprint of a disease 
(15). In theory, luminescence-based 
imaging modalities have a contrast 
agent sensitivity that is similar to 
that of US and nuclear medicine tech-
niques (1029 to 10212 mol), also en-
abling the visualization of molecular 
features (15). Here it should be noted 
that increasing the concentration of a 
Radiology: Volume 276: Number 1—July 2015 n radiology.rsna.org 19
REVIEW: Luminescence-based Approaches in  Interventional Molecular  Imaging van Leeuwen et al
fluorescent dye does not always lead 
to an increase in its fluorescent signal 
intensity; dye-dye interactions may 
result in a decreased emission signal, 
so-called self-quenching (16).
Luminescence Imaging Systems
Luminescence-based optical imaging 
can be applied in a number of differ-
ent ways and has already been suc-
cessfully integrated in endoscopic (eg, 
laparoscopy, colonoscopy, bronchos-
copy) and open-surgery procedures. 
Herein, luminescence-based imaging 
can allow high-resolution identifica-
tion of superficial lesions (, 1 cm) 
(17). In general, the use of lumines-
cent tracers has been driven by the 
commercial availability of lumines-
cence imaging devices from estab-
lished companies such as Olympus 
(Tokyo, Japan), Karl Storz GmbH & 
Co KG (Tutlingen, Germany), Hama-
matsu Photonics (Hamamatsu, Ja-
pan), Novadaq (Mississauga, Cana-
da), and Intuitive Surgical (Sunnyvale, 
Calif). Many of these companies have 
a historic background in white light 
imaging and the visualization of lumi-
nescent tracers that emit light in the 
visible part of the spectrum (eg, pro-
toporphyrin IX derivatives and fluo-
rescein) or the visualization of tissue 
autofluorescence. Since the concept 
of luminescence imaging is the same 
across the light spectrum, a relatively 
straightforward modification of pre-
existing cameras now enables efficient 
detection of light in the near-infrared 
region of the light spectrum. The pace 
of these developments is stunning and 
the quality of the interventional im-
ages obtained has already reached 
full high-definition views, where the 
near-infrared fluorescent tracers used 
for angiography or sentinel node pro-
cedures can be accurately detected 
in real time and within the anatomic 
context of the specific patient (Fig 3). 
These efforts are further strength-
ened by an increasing number of 
small companies and research groups 
that are involved in the generation 
of alternative imaging devices; well-
known examples of camera systems 
for open-surgery procedures are the 
FLARE camera (the FLARE Founda-
tion, Wayland, Mass) (18), the Fluop-
tics camera system (Fluoptics, Greno-
ble, France) (19), and the SurgVision 
camera (SurgVision, Heerenveen, 
the Netherlands) (20). Interesting to 
mention in this context is also the ex-
perimental hands-free goggles system 
from Liu et al (21,22).
Microscopic optical imaging has 
been widely explored in ophthalmology 
(23) and in neurosurgery (24,25). For 
these indications, the areas of interest 
are in a known and stable location of 
the body, and as a result, clinical fluo-
rescence microscopes like those of 
Leica Camera (Nussloch, Germany) 
and Carl Zeiss (Jena, Germany) can be 
used. Although the name suggests oth-
erwise, these fluorescence microscopes 
only provide a submillimeter resolution. 
Nevertheless, this submillimeter resolu-
tion was shown to enable the detection 
of malformations in small blood vessels, 
thereby improving, for example, the ac-
curacy of clipping in patients with a ce-
rebral aneurysm (26).
More recently there has been a 
drive toward the use of small fiber-
based microscopic optical devices that 
can be applied during interventions. 
Commercially, modalities are available 
from, for example, Optiscan (Victoria, 
Australia), Mauna Kea Technologies 
(Paris, France), and Olympus. These 
systems explore fluorescence imag-
ing to provide immediate microscopic 
feedback on the tissue histology and/
or morphology of lesions (27,28), en-
abling so-called optical tissue biopsy. 
It should be mentioned that there is 
a long way to go before such technol-
ogies can replace conventional histo-
logic evaluation. The image resolution 
that can be obtained ranges between 
1 and 10 mm (the diameter of a tumor 
cell is approximately 10 mm). While 
endocytoscopy only allows superficial 
imaging at this resolution, confocal 
laser endomicroscopy enables up to 
250-mm deep in-plane visualization 
(27) and confocal mini laparoscopy 
even reaches 350 mm (29).
Research efforts to improve the in 
vivo detection of luminescent tracers 
in an interventional setting focus on a 
number of features. First, the sensitivity 
of camera systems, meaning the ability 
to effectively collect luminescence emis-
sions, is a critical feature. In our own 
studies we noted that in prostate can-
cer patients, sentinel node detection 
rates significantly improved from 85.2% 
to 93.5% when the fluorescence imag-
ing system was improved from a stan-
dard analog image projection to a more 
sensitive digital high-definition system 
(30). It can thus be assumed that fur-
ther improvement of camera sensitivity 
is likely to have a comparable positive 
effect on the usability of fluorescence 
cameras during interventions. Espe-
cially when looking at targeted tracers, 
where only small tracer amounts reach 
the target lesion, sensitivity of the cam-
era system will determine whether or 
not the lesion can be visualized during 
the intervention. Also, during Cerenkov 
luminescence imaging of b emissions, 
this effect can be great (1). While ded-
icated camera development for Ceren-
kov imaging is still in its infancy, this 
area of research is already producing 
some promising results (31,32).
Second, the ability to overlay the 
fluorescence signal onto the normal 
white light image may help to further 
incorporate the use of luminescence-
based optical imaging in clinical logis-
tics. In doing so, simultaneous visuali-
zation of the fluorescence signal and the 
anatomic structures (Fig 3, A) enables 
actual lesion excision under fluores-
cence guidance (30). While some op-
tical modalities separately detect the 
white light and fluorescence images be-
fore overlaying them, the recent trend 
is to use a single (multichip) camera 
to detect both features and provide a 
fully integrated fluorescence and back-
ground image.
Third, while fluorescence emissions 
such as that of fluorescein can be de-
tected by the naked eye and therefore 
show up in their natural color (in this 
case yellow and/or green), red fluores-
cence gives significantly less contrast 
over a surgical background and may 
need some form of artificial coloring for 
optimal contrast. Near-infrared emis-
sions, which cannot be detected by the 
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naked eye, can only be visualized by us-
ing a dedicated camera with strict filter 
settings. Here the near-infrared signal 
is either presented in black and white 
or pseudo color coding is used. Figure 
3, B, illustrates the influence that color 
selection has on the visual interpreta-
tion of the image; green gives a much 
stronger visual contrast with its back-
ground than blue and as such can be 
better detected. Signal intensities can 
also be presented by using heat-map 
features, thereby giving more quanti-
tative feedback on, for example, perfu-
sion during surgery (Fig 3, C) (26).
Fourth, the possibility to detect 
multiple but distinct optical emissions 
with one camera system (called multi-
spectral imaging or multiplexing) has 
become a topic of interest. The ability 
to detect different types of fluorescence 
signals means that different anatomic, 
physiologic, and/or molecular param-
eters can be visualized simultaneously 
or sequentially. An example of this 
concept is provided in Figure 3, D, in 
which accumulation of the near-infra-
red tracer ICG-99mTc-nanocolloid in the 
sentinel node (blue, i) is complemented 
by detecting the lymphatic flow toward 
and through the same sentinel node 
with fluorescein (green/yellow, ii).
Lastly, to make sure the user will 
not get lost in the level of detail pro-
vided, for example when using fiber-
based optical devices (Fig 3, E), device 
placement, tracking, and stabilization 
are of upmost importance. If fibers 
are small enough, they can be placed 
through a cholangioscope (33) or can 
be passed through a fine needle aspira-
tion cytology needle (34). When placed 
under radiologic guidance, one may en-
vision that (optical) needle placement 
may rapidly find an application in min-
imally invasive treatment strategies. 
This technology may potentially be of 
added value during target validation 
and the assessment of margins prior 
to the application of minimally invasive 
treatment strategies such as radiofre-
quency ablation, microwave ablation, 
or irreversible electroporation ablation. 
For the moment, clinical indications of 
fiber-based technologies are still mostly 
being defined to luminal organs such as 
the esophagus and gastrointestinal tract 
(35).
Luminescence Tracers
Three main families of luminescence-
based exogenous tracers have been 
reported in clinical trials: fluorescent 




means of visualizing the vascular physiol-
ogy can be used to provide an alternative 
to contrast-enhanced radiologic tech-
niques. For example, iodinated fluores-
cein derivatives (55% iodine by weight) 
were described as early as 1949 as con-
trast agents for both x-ray fluoroscopy 
and fluorescence imaging after intrave-
nous cholecystography (36). In this ini-
tial study, gallbladder visualization was 
achieved in 13 of 35 patients. Since then 
noniodinated fluorescein, which has a 
limited toxicity, has received regulatory 
approval for angiography. The clinical 
evaluation of fluorescein was followed by 
the clinical approval of its near-infrared 
counterpart ICG (37). The vascular re-
tention of ICG, a dye that immediately 
binds to “large” carrier proteins such 
as human serum albumin in situ, has 
been used to assess organ perfusion in 
different anatomies. Examples include 
tissue vitality (eg, free-flap reconstruc-
tion [38]), partial nephrectomy with 
selective arterial clamping (39–41), re-
constructive surgery of the upper uri-
nary tract (39), or the microscopic as-
sessment of vascular malformations in 
the brain (37). With regard to the ap-
plication of ICG for angiography, during 
partial nephrectomy ICG cannot only be 
used to locate the artery (Fig 4, A), it 
can also be used to distinguish normal 
parenchyma from cysts and tumors; the 
latter appear hypofluorescent relative to 
the normal parenchyma (39–41).
Other than perfusion, extravasation 
of fluorescent tracers into tissue—a fea-
ture that is similar to late contrast en-
hancement at MR imaging—was shown 
to provide feedback on the physiology. 
For example, the impaired vascular net-
work of tumors in the eye is routinely 
assessed by using fluorescein (23), while 
in a more experimental setting the same 
has been done for the brain (42). The 
value of this approach is exemplified 
by the fact that in two patients (total 
number of patients in this study was 
five), in whom x-ray angiography failed 
to show a vascular flush, the finer and 
sharper contrast obtained by using fluo-
rescence imaging helped to demarcate 
the tumor tissue based on abnormalities 
in the vascular bed (42). Alternatively, 
in 46 patients clinically diagnosed with 
a brain tumor, fluorescein-based imag-
ing of the needle biopsy specimen and 
subsequent tumor resection correctly 
predicted the prescence or absence of 
a tumor in 44 patients (4). Extravasa-
tion of fluorescein also allowed the iden-
tification of microscopic changes of le-
sions located in the gastrointestinal tract 
(35). The pH dependancy of fluorescein, 
where the intensity of the fluorescence 
emission changes upon changing pH, 
helped to identify small biologic changes 
in the lesion. Moreover, morphologic 
changes and changes in vascularity could 
be identified by using fluorescein. The 
latter is illustrated in Figure 3, E, which 
shows an area with increased perme-
ability and therefore increased fluores-
cein extravasation (35).
Other dyes that have been shown to 
accumulate in tumor tissue, for example, 
breast tumors, are ICG, omocyanine, 
and methylene blue (43–46). Depending 
on the dose administrated, omocyanine 
was able to visualize malignant lesions 
smaller than 2 cm. However, detection 
rates strongly decreased with increasing 
skin-to-lesion distance; 63.6% of lesions 
were detected at skin-to-lesion distance 
of less than 2 cm whereas only 25% were 
detected at a distance greater than 3 cm 
(44). Using ICG, Poellinger et al showed 
a 92.0% sensitivity and 75.0% specificity 
for optical mammography (43). Never-
theless, it was concluded that the tech-
nique of optical mammography on its own 
has insufficient diagnostic accuracy and 
should be combined with conventional 
tools (47). Ex vivo fluorescence imaging 
of breast cancer specimens following 
intravenously administered methylene 
blue revealed accumulation of the dye in 
83.3% of the resected tumors (45).
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Figure 4
Figure 4: Different applications of nontargeted fluorescence tracers. A, Intravenous administration of ICG 
can be used to visualize blood vessels during partial nephrectomy (fluorescence in green; arrow = clamped 
artery, dotted arrow = affluent vein; the large green mass is the kidney). B, Extravasation of methylene blue 
can be used to visualize parathyroid adenoma(s) during surgery (fluorescence in green; arrow = location of 
the parathyroid adenoma). C, Disruptions in the hepatic clearance of ICG can be used to visualize hepato-
cellular lesions in the liver (fluorescence in black and white). The insert shows the corresponding white light 
image. (Reprinted, with permission, from reference 135.) D, Local injections of ICG-99mTc-nanocolloid sur-
rounding squamous cell carcinoma of the tongue (insert) show prolonged accumulation at the injection site. 
The fluorescence signal is shown in black and white, with the near-infrared fluorescence signal displayed in 
white. (Reprinted, with permission, from reference 67.) 
Methylene blue has also been rou-
tinely used to visualize parathyroid le-
sions via its true blue color (48). In a 
similar fashion, recently fluorescence 
imaging of low-dose methylene blue 
identified a parathyroid adenoma in nine 
of 12 patients scheduled for parathyroid 
surgery; only seven of these nine patients 
had a positive 99mTc-sestamibi SPECT-
CT scans (49). Unfortunately, it was not 
reported what might have caused this 
differential uptake. Although the up-
take mechanisms of these tracers were 
initially assumed to be identical, the 
latter finding suggests that there might 
be a difference in uptake mechanism 
between the two. Hence, the mode of 
accumulation of methylene blue is most 
likely also the result of extravasation.
The pharmacological clearance of 
nontargeted fluorescent tracers can also 
be exploited for diagnostic purposes. 
Functional hepatic clearance of ICG was 
shown to aid in the visualization of bile 
ducts during cholangiography (50,51). 
Impairments in the clearance mecha-
nism, combined with expression of the 
sodium ion/taurocholate cotransporting 
peptide and organic anion transporting 
polypeptide 8 by hepatocellular cancer 
cells, was shown cause ICG accumula-
tion in the cells, resulting in highly sen-
sitive fluorescence-based identification 
of these tumors in the liver (52). In this 
particular study, which included 273 
patients, ex vivo fluorescence-based tis-
sue examination enabled the identifica-
tion of 98.9% of the hepatocellular car-
cinoma lesions. Here retention of ICG 
was similar to what is observed during 
contrast-enhanced CT or MR imaging 
of such lesions (53), but the resolution 
achieved via fluorescence imaging on 
the surface of the liver was superior. 
For the detection and/or treatment of 
deeper-lying lesions, conventional US-
based technologies are still mandatory.
Renal clearance of dyes such as 
fluorescein (n = 12) and methylene blue 
(n = 12) was shown to provide a means 
to visualize ureters (54,55).
Local administration.—Following a 
local injection, fluorescent dyes can be 
used for lymphangiography (56–59). Ini-
tially radiopaque contrast agents were 
used, but currently lymphatic mapping 
is dominated by the use of radiotracers 
(60–62). Local injections with fluores-
cein or ICG have been proposed as a 
more sensitive alternative to blue dye 
(63) and a more convenient approach 
than the use of gamma tracing (64,65). 
Although the lymphatic drainage of ICG 
and blue dyes is the same, Guo et al (66) 
reported the fluorescence approach be-
ing more sensitive for the detection of 
the sentinel node, 97.2% versus 81.3%, 
respectively. The difference in detection 
mechanisms, namely the detection of an 
emitted signal by a light-sensitive cam-
era (fluorescein and/or ICG) versus the 
detection of light absorbance by the eye 
(blue dye) provides the most plausible 
explanation for this difference in sensi-
tivity. The relatively limited tissue pen-
etration of the fluorescence signal, com-
pared with the radioactive signal, can be 
of value during the detection of lymph 
nodes located in close proximity to the 
injection site (67).
Interventional guidance toward 
nonpalpable lesions detected at preop-
erative imaging, for example, nonpal-
pable breast cancer, is often provided 
via guide-wire localization, radioguided 
occult lesion localization (using radio-
colloids), or radioactive seed localiza-
tion (using titanium marker seeds filled 
with a small amount of radioactive io-
dine). In this application, preoperative 
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Figure 5
Figure 5: Targeted luminescent tracers. A, Folate-FITC can be used to visualize folate receptor-overex-
pressing lesions of the surface of the ovarium. The fluorescence image is shown in black and white, with the 
fluorescence signal displayed in white. The insert shows the corresponding white light image. (Reprinted, 
with permission, from reference 75.) B, Intravenous administration of GE137 was shown to highlight can-
cerous lesions during colonoscopy (fluorescence in green). The insert shows the corresponding white light 
image. C, Topical administration of CEA-mAb-FITC can enable visualization of cancerous lesions in the lumen 
of the colon (fluorescence in green). The insert shows the corresponding white light image. (Reprinted, with 
permission, from reference 74.) D, Cerenkov luminescence imaging (luminescence in red) can be used to 
optically identify 18F fluorodeoxyglucose accumulation in a lymph node. The insert shows the corresponding 
PET-CT image. (Reprinted, with permission, from reference 32.) 
radiologic imaging such as US or x-ray 
guidance is used to mark the area that 
needs further investigation. In a simi-
lar fashion, fluorescent markers may be 
used to stain the area of interest (12). 
An ICG-labeled radiocolloid (Table 2) 
has already shown its ability to accumu-
late at the injection side of oral cavity 
cancers or prostate for a longer period 
of time (67,68). In the gastrointestinal 
tract, a local injection of blue dye is 
widely used to enable accurate lesion 
localization during ex vivo (pathologic) 
examination (69), suggesting the same 
may be performed in the future by us-
ing fluorescent tracers.
Topical administration.—Topical 
administration of a fluorescent tracer, 
whereby the tracer is locally sprayed 
on the area of interest, may be used to 
provide direct feedback during the in-
tervention. Confocal endomicroscopy of 
the gastrointestinal mucosa after topical 
administration of acrilflavine (hydrochol-
oride) showed increased uptake in areas 
with an increased cell density (cell nu-
clei) (70). However, compared with in-
travenous administration of fluorescein, 
which allowed labeling of the cells up to 
the lamina propria, acriflavine was only 
able to label superficial epithelial cells 
(71). Cresyl violet, a dye that stains 
the cytoplasm rather than the nucleus, 
has been proposed as an alternative for 
chromoendoscopy and fluorescein endo-
microscopy (n = 36) (72).
Targeted Fluorescent Tracers
Intravenous administration.—When tar-
geted fluorescent tracers are used for the 
evaluation of molecular parameters, the 
mechanism of action is similar to that 
of radiotracers: An intravenous bolus 
administration allows targeting of mem-
brane receptors expressed on the tumor 
cell surface. In fact, the optical field of-
ten explores targeted approaches pre-
viously reported by using radiotracers. 
Since optical labels are relatively large, 
fluorescent tracers are commonly based 
on disease-specific peptides or mAbs. 
Examples of studied molecular targets 
are CEA (73,74), the folate receptor 
(75), the receptor tyrosine kinase c-met 
(5,76), the EGFR (77), and the vascular 
endothelial growth factor receptor (78).
Unfortunately, in biomarker-
targeted interventions that rely on 
fluorescent tracers only, the limited 
penetration depth of the fluorescence 
signal is a considerable weakness. Ac-
cumulation in unsuspected areas can-
not be assessed, thereby potentially 
limiting the curative intent of surgery. 
It is also not possible to use fluores-
cence to noninvasively stage whether 
or not the tracer used is of value for 
an individual patient. An example 
is the limited success rate of folate 
FITC reported in patients with ovar-
ian cancer (75). These problems can 
be solved when a radiotracer for the 
same target is used to noninvasively 
assess the targeting ability, location, 
and spread of the disease.
In contrast, when the location of a 
lesion is known, real-time and high-reso-
lution superficial identification of lesions 
become possible. Successful examples of 
this are the visualization of superficially 
located ovarian cancer lesions by using 
folate FITC (in three of 10 patients one 
or more malignant tumor lesions could 
be identified intraoperatively; Fig 5, A 
[75]) and the identification of colorectal 
neoplasia by using the compound GE137 
(Cy5 labeled; Fig 5, B), which targets 
the c-met receptor (5). For the latter, 
second-pass fluorescence imaging iden-
tified 19% additional lesions (5).
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Topical administration.—Topical 
tracer application is increasingly being 
explored to locally visualize molecular 
tumor features by using either targeted 
or activatable fluorescence tracers. This 
approach makes sense especially when 
the intention is to further characterize 
lesions that have been detected previ-
ously by radiologic or standard endo-
scopic methods. Topical methods are 
therefore not intended to aid in the 
primary detection of, for example, colo-
rectal neoplasms but to microscopically 
analyze lesions to predict their histol-
ogy and/or local extent.
A number of compounds have been 
evaluated in vivo in humans for the char-
acterization of lesions in the colon, rang-
ing from dysplasia to cancerous lesions. 
A CEA-targeted mAb (CEA-mAb-FITC; 
Fig 5, C) was used to target CEA over-
expression. In 27 patients, an increased 
fluorescence signal was found in 19 of 25 
carcinomas and three of eight adenomas 
after local application of the probe (74). 
A FITC-labeled heptapeptide (VRPM-
PLQ-FITC) has been used to character-
ize colorectal neoplasia by binding to 
a yet unknown molecular target. In 20 
patients, confocal endomicroscopy was 
used to differentiate adenoma from nor-
mal tissue after topical adminstration of 
the dye in the colon, with 81.0% sen-
sitivity and 82.0% specificity (79). An 
anti-EGFR mAB coupled to Alexa Fluor 
488 was used to target EGFR-overex-
pressing colorectal polyps from 37 pa-
tients; a specific fluorescence signal and 
EGFR accumulation could be detected 
in 18 (94.7%) of 19 carcinomas and 12 
(66.7%) of 18 adenomas (77).
The FITC-labeled peptide sequence 
ASYNYDA-GGGSK, isolated with 
phage display biopanning by using 
an esophageal cancer cell line, which 
probably targets cyclophilin A, has 
been evaluated for the detection of 
esophageal neoplasia within Barrett 
esophagus by using confocal endomi-
croscopy. In 25 patients there were 
nine true-positive, one false-positive, 
34 true-negative, and three false-neg-
ative findings for identifying neoplasia, 
resulting in a positive predictive value 
of 90.0% and a negative predictive 
value of 91.9% (80).
Topical administration of enzyme-
activated tracers is attractive in that 
they should be able to achieve higher 
target-to-background ratios with no 
background signal from the quenched, 
inactivated tracer and a multiplication 
of the signal due to enzymatic activation 
of the probe at the site of enzyme over-
expression. In ex vivo human breast 
and lung cancer tissues it was shown 
that the enzyme g-glutamyltranspepti-
dase was able to activate the topical dye 
gGlu-HMRG, resulting in fluorescent le-
sions (81). The future challenge mainly 
lies in the identification of identical, 
or complementary, radiologic features 
that can be used to guide physicians in 
their topical administration of (activat-
able) fluorescent tracers. In essence, 
the guidance required for topical tracer 
administration is highly similar to the 
guidance needed to acquire biopsy 
specimens of a diseased area.
Hybrid Tracers
Tracers combining a radioactive and a 
luminescent signature allow for initial 
identification of the lesion at conven-
tional preinterventional imaging (eg, 
SPECT or PET), followed by intraop-
erative luminescence guidance. Here 
the radioactive signal of hybrid tracers 
overcomes the major shortcoming of 
optical imaging, namely in-depth sig-
nal penetration. On top, it opens the 
field for the use of non–near-infrared 
luminescence emissions during inter-
ventional guidance; with the radioac-
tive signal providing an in-depth view, 
optical detection can be of value even 
when it is highly superficial in nature.
Two subclasses of luminescence-
based hybrid tracers have been report-
ed for clinical use, namely tracers that 
combine a radio and fluorescent label 
and radioisotopes that enable Ceren-
kov luminescence imaging (Table 2). 
Other than the fluorescent tracers 
described above, hybrid tracers have 
only been used in combination with 
intravenous and local administration.
Combination of a radioisotope 
and a fluorescent dye.—To date, only 
two combined radioactive and fluo-
rescent hybrid approaches that have 
been reported in clinical studies use 
131I-fluorescein (82,83) and ICG-99mTc-
nanocolloid (10,30,84,85). For the ex-
citation and emission of these agents, 
the same rules apply as for the con-
ventional fluorescent tracers (illus-
trated in Fig 2).
Intravenous administration of 131I-
fluorescein was first reported in 1948 
as a vascular contrast agent for the 
detection of disrupted vascularization 
of brain tumors (82). Here, the iodine 
compound was used to noninvasively 
assess the degree of accumulation prior 
to the intervention. Preoperative im-
aging findings overlapped with surgical 
findings in 11 of 12 patients (82).
The hybrid tracer ICG-99mTc-nano-
colloid is a lymphatic agent that is com-
posed of the commercially available 
radiolabeled human serum albumin col-
loid (nanocolloid) and ICG (84). Similar 
to the parental radiocolloid, following a 
local peritumoral injection the hybrid 
tracer accumulates in sentinel nodes 
(84). This compound has been eval-
uated in more than 500 patients and 
has proven valuable for sentinel node 
procedures at different sites, such as 
melanoma, penile cancer, and prostate 
cancer (10,30,84,85). The combined 
approach was shown to be superior 
to radioguidance technologies alone. 
It has aided in optimizing the logistics 
and improved the detection of sentinel 
nodes residing in a complex anatomy 
(Movie [online]).
Although the fluorescent properties 
of methylene blue have not yet been 
explored for radioiodinated (123I, 125I, 
or 131I) methylene blue, in theory this 
compound can be considered a hybrid 
tracer. Practically this would mean that 
all the diagnostic applications of meth-
ylene blue can be complemented by in-
depth in vivo guidance via gamma sig-
nal detection. Early studies indicated 
methylene blue an unsatisfactory para-
thyroid imaging agent (86), but is said 
to be of value in the detection of mel-
anoma metastases (87). In melanoma, 
gamma tracing of radioiodinated meth-
ylene blue confirmed the existence of 
approximately 80% of the lesions and 
enabled detection of secondary lesions 
in six of 12 patients. Alternatively, the 
radiolabel on methylene blue may be 
24 radiology.rsna.org n Radiology: Volume 276: Number 1—July 2015
REVIEW: Luminescence-based Approaches in  Interventional Molecular  Imaging van Leeuwen et al
Figure 6
Figure 6: Therapeutic agents that can be used for luminescence imaging. A, After administration of 
doxycycline (fluorescence in yellow), necrotic areas in the jaw become hypofluorescent. The insert shows the 
corresponding white light image. (Reprinted, with permission, from reference 95.) B, Local instillation of hexyl 
aminolevulinate (HAL) (fluorescence in red) can be used to identify cancerous lesions in the bladder wall. 
(Reprinted, with permission, from reference 136.)
used to provide radioguidance during 
lymphatic mapping, as was shown in 
an initial feasibility study in 12 women 
scheduled for breast cancer–based 
sentinel node biopsy (88).
While the use of radiolabeled fluo-
rescein and methylene blue indicates 
that iodination may be acceptable for 
small molecules, the success of ICG-
99mTc-nanocolloid may also be repre-
sentative for fluorescence labeling of 
large protein-based radiotracers such 
as antibodies. Theoretically, radio-
tracers used for SPECT, PET, and ra-
dioguided surgery can all be chemically 
modified into hybrid tracers. The same 
goes for US and MR imaging contrast 
agents. However, one should consider 
that modification of an established ra-
diotracer may negatively influence its 
affinity, pharmacokinetics, and biodis-
tribution (89,90).
Use of a radioisotope that also al-
lows for Cerenkov luminescence.—De-
spite having an emission peak in a part 
of the light spectrum that has minimal 
tissue penetration (, 200 nm), the 
first studies in humans yielded prom-
ising results. A therapeutic dose of 131I 
(550 MBq) was used for luminescence 
imaging of the thyroid in a single pa-
tient (31). In patients with lymphoma 
(n = 2), lung (n = 1), or breast (n = 
1) cancer, after routine 18F-FDG PET-
CT imaging (450 MBq), Cerenkov lu-
minescence imaging revealed the site 
of accumulation in the 18F-FDG PET–
positive lymph nodes in the neck and 
axilla (Fig 5, D) (32). Although imag-
ing cannot yet occur at video rate, the 
current detection sensitivity achieved 
is exceptional when one considers that 
the photon flux from 18F is orders of 
magnitudes smaller than that of widely 
used fluorescent dyes (1). Crucial in 
the success of this imaging technique 
is the ability to determine the area of 
interest prior to the intervention by us-
ing the acquired PET-CT images.
Theranostic Tracers
Next to their use for therapy purposes, 
theranostic compounds can also pro-
vide optical feedback during interven-
tions. For the excitation and emission 
of these agents, similar rules apply 
as those for fluorescent and hybrid 
tracers (Fig 2). An example of a group 
of theranostic agents can be found in 
cycline derivatives. Following internal-
ization, fluorescence imaging of tet-
racycline, doxycycline, and demecocy-
cline was shown to distinguish viable 
bone tissue from the nonfluorescent 
necrotic tissue (91–96). With doxo-
cycline, prior to fluorescence imaging 
patients required the drug to be ad-
ministered in a 10-day administration 
regimen (Fig 6, A) (95).
Alternatively, photodynamic ther-
apy, a minimally invasive ablation tech-
nology, can be combined with photody-
namic diagnosis (PDD). This procedure 
is based on the concept of intravenous 
administration of a compound that ac-
cumulates more specifically in tumor 
cells than in normal tissue (extensively 
reviewed by Celli et al [97]). Following 
entrapment of the agent in malignant, 
inflammatory, and/or infected tissue 
(98), it as metabolized into the fluo-
rescent compound protoporphyrin IX; 
well-known protoporphyrin IX pre-
cursors are ALA, hexyl ester of ALA 
(HAL), and methyl ester of ALA (MAL) 
(Table 3). Although 5-ALA, HAL, and 
MAL all have all been used in similar 
applications such as PDD of brain tu-
mors, skin, and bladder cancer, HAL 
and MAL are considered superior to 
5-ALA (97). This effect may well be 
related to the formulation used, since 
the ability of these compounds to in-
duce more protoporphyrin IX is still 
somewhat controversial (99). Following 
intravenous administration of 5-ALA, 
fluorescence-guided malignant glioma 
excision versus white-light–based ex-
cision was evaluated in a randomized 
cohort of 322 patients and yielded a 
higher 6-month progression-free sur-
vival than that in the patients assigned 
to white light only (41.0% vs 21.1%, 
respectively) (100). Alternatively, blad-
der-instilled HAL (Fig 6, B) improved 
the accuracy of white-light cystoscopy 
in lesion detectability, from 75.3% to 
86.7%, respectively (101). The pre-
formed porphyrin derivative meta-
tetrahydroxyphenylchlorin has been 
used for PDD of brain and oral cavity 
tumors. In 22 patients, a sensitivity of 
87.9% and a specificity of 95.0% were 
found for brain tumor detection (102).
Hypericin, a natural compound de-
rived from the Hypericum perforatum 
plant (mechanism of tumor accumu-
lation unknown), has been success-
fully used for the detection of blad-
der cancer, with a specificity ranging 
91%–98%. Compared with other PDD 
agents, it was claimed to reduce the 
incidence of false-negative findings 
(103).
A clear downside of the above-
mentioned theranostic agents is the 
Radiology: Volume 276: Number 1—July 2015 n radiology.rsna.org 25
REVIEW: Luminescence-based Approaches in  Interventional Molecular  Imaging van Leeuwen et al
unavailability of a complementary non-
invasive imaging method that can be 
used to select patients who would ben-
efit most from the above procedures.
Current Status and Future Directions
Luminescence-based optical imaging has 
already been applied in a variety of in-
terventional settings. From these stud-
ies the strengths and weaknesses of the 
technology can be derived. The main 
strength of luminescence imaging lies in 
its ability to provide real-time feedback 
regarding the location and margins of 
a lesion on a microscopic or molecular 
level. The main weakness of lumines-
cence imaging is its intrinsic inability to 
look deep into the tissue. On its own, it 
can, therefore, only be of value for the 
identification of lesions with a known or 
superficial location in a lumen or cavity 
accessible with a camera.
For luminescence guidance to be 
minimally invasive, patients should 
have already been accurately staged 
by using noninvasive radiologic or nu-
clear medicine imaging technologies. 
This is especially important when an 
attempt is made to depict molecular 
features of a disease. When a prein-
terventional imaging approach matches 
the interventional use of luminescence 
imaging, potentially a “best of both 
worlds” scenario is generated, with de-
tailed feedback on the disease and its 
extent. Hence, luminescence imaging is 
unlikely to replace existing radiologic 
and nuclear medicine technologies, but 
will provide a valuable add-on to exist-
ing interventional imaging approaches.
The efficient integration of lumines-
cence imaging with other radiologic- or 
nuclear-medicine–based modalities may 
be accomplished by using either se-
quential imaging with different tracers 
or by using a hybrid imaging approach, 
wherein a single tracer can be detected 
with two complementary modalities. If 
the location of a lesion can already be 
defined accurately prior to the interven-
tion, a luminescent tracer can be used 
to visualize complementary rather than 
identical features, for example, blood-
flow kinetics (26). The reverse is also 
true, as radiologic modalities such as 
C-arm, CT, or US may be used to pro-
vide anatomic context for physiologic or 
molecular features depicted with lumi-
nescence imaging technologies.
Integration of Luminescence-based 
Imaging in the Clinical Workflow
The availability of this “new” type of im-
aging modality presents practical chal-
lenges when it comes to its integration 
into the clinical workflow. For that rea-
son, future developments should also im-
prove the clinical utility of the technique. 
For example, in open surgery, most of 
the currently available luminescence im-
aging camera systems require the lights 
in the operating room to be dimmed or 
switched off completely to allow for the 
optimal identification of (near-infrared) 
luminescence signals (5,84,104). De-
spite the ongoing developments to inte-
grate luminescence imaging into surgical 
goggles (21,22), the feedback provided 
by luminescence imaging is generally 
depicted on a screen. In open-surgery 
procedures, this feature complicates 
the routine and requires training before 
it can be used optimally. This is not a 
limiting factor in microscopic or endo-
scopic applications, where interventions 
are already routinely performed by using 
an on-screen video feed, and integration 
of luminescence-based information only 
has a limited influence on the workflow 
(5,13,26). One unique example where 
luminescence imaging has even become 
an integral part of the surgical tools is 
found in robotic surgery (39–41); the da 
Vinci Si robot (Intuitive Surgical) can be 
equipped with an endoscope suitable for 
near-infrared imaging.
Optical Properties of Clinically Used 
Fluorescent Dyes
For interventional guidance, there has 
been a scientific push toward the use of 
near-infrared dyes. Unfortunately, the 
signal intensity of near-infrared dyes 
is severely limited by their low photon 
flux. The ideal exogenous fluorescent 
dye combines a high absorption coeffi-
cient with a high quantum yield, yield-
ing optimal conversion of light. The 
limited emission strength of near-in-
frared dyes is partially compensated 
by the fact that excitation and emission 
of these dyes occur in the “most ideal” 
section of the light spectrum, yielding 
minimal autofluorescence and signal 
attenuation. Nevertheless, with the ex-
ception of ICG, CW800, and omocya-
nine, all other luminescent tracers that 
have been evaluated in clinical trials 
emit outside the near-infrared spec-
trum (200–780 nm; Tables 1–3). Note 
that the term near-infrared is often 
wrongly used to describe excitations 
and emissions below 780 nm.
For molecular luminescence imag-
ing in particular, next to the near-in-
frared tracers, Cerenkov luminescence 
imaging, PDD contrast agents, fluores-
cein derivatives, and a Cy5 derivative 
have shown their value in the clinic. 
This suggests that the tissue penetra-
tion efficiency of the luminescence sig-
nal is not necessarily a limiting factor 
for their clinical use. Depending on the 
application, the best balance between 
signal intensity and penetration depth 
should be sought.
Future Targets for Luminescence Imaging
Tables 1–3 indicate that luminescence 
imaging can be used to depict a variety 
of anatomic, physiologic, and molecular 
features. Clinical trials have boosted 
preclinical efforts to improve the lumi-
nescence properties and explore new 
targets, yielding a wide variety of po-
tential imaging agents. From a chemical 
perspective, there are few restrictions 
for the future design of different lumi-
nescent dyes and new tracers.
Hybrid approaches are increasingly 
being pursued in preclinical studies. The 
chemical variations are only limited by 
the number of radioisotopes available 
for imaging purposes. While essentially 
any luminescence tracer can be chem-
ically modified into a hybrid deriva-
tive (90,105), it is not trivial to do the 
reverse; the size of a fluorescent dye may 
be noticeably larger than the size of the 
radioisotope used. Although the com-
bination of luminescence and nuclear 
labels provides the best fit with regard 
to interventional use and contrast sen-
sitivity, combinations can also be made 
between luminescence and, for example, 
MR imaging contrast (106).
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Clinical Availability
While compounds such as ICG and fluo-
rescein have found their way into clinical 
routine, most of the other tracers dis-
cussed have not yet progressed beyond 
small first human trials. Even in more 
routine applications, such as sentinel 
node procedures, clinically approved 
compounds are often still being used off-
label. On the basis of the amount of suc-
cessful trials reported, it is highly likely 
that in the near future the amount of lu-
minescent tracers will expand. However, 
all of these new luminescent tracers will 
need to be approved for human use in-
dividually. Combined with the costs as-
sociated with getting this approval, this 
may limit the number of tracers that will 
find their way into the clinical routine. In 
this setting, Cerenkov luminescence im-
aging, an imaging option that is directly 
derived from the already approved PET 
tracers, seems to have a big advantage.
Conclusion
Although much has to be done before 
the highly superficial luminescence-
based imaging technologies replace 
existing guidance technologies, the 
outcome of a variety of clinical trials 
with luminescent tracers suggests the 
technology may help provide physicians 
with real-time and detailed (molecular) 
feedback during an intervention. More 
extensive multicenter trials are, how-
ever, required to determine how the 
use of luminescence technologies will 
affect clinical outcome.
Disclosures of Conflicts of Interest: F.W.B.v.L. 
Activities related to the present article: received 
grants from Dutch cancer society. Activities not 
related to the present article: disclosed no rele-
vant relationships. Other relationships: disclosed 
no relevant relationships. J.C.H.H. Activities re-
lated to the present article: institution received 
money from GE Healthcare; subcontracted by 
the Centre for Human Drug Research, Leiden, 
to perform endoscopies for human safety stud-
ies and a patient study of GE-137 optical mo-
lecular imaging agent (Euro 50,000). Activities 
not related to the present article: disclosed no 
relevant relationships. Other relationships: dis-
closed no relevant relationships. A.R.v.E. dis-
closed no relevant relationships.
The authors declare to have no conflicts of inter-
est and no commercial links with the industry. 
They, however, are or have been involved in clin-
ical fluorescence-guided surgery trials that KARL 
STORZ GmbH & Co. KG, Eurorad, Hamamatsu 
Photonics, and GE Healthcare support(ed) by 
making luminescence imaging hardware available.
References
 1. Chin PT, Welling MM, Meskers SC, Valdes 
Olmos RA, Tanke H, van Leeuwen FW. 
Optical imaging as an expansion of nuclear 
medicine: Cerenkov-based luminescence vs 
fluorescence-based luminescence. Eur J Nucl 
Med Mol Imaging 2013;40(8):1283–1291.
 2. Yang X. Interventional molecular imaging. 
Radiology 2010;254(3):651–654.
 3. Policard A. Étude sur les aspects offerts 
par des tumeurs expérimentales examinées 
à la lumière de Wood. C R Soc Biol Paris 
1924;91:1423–1424.
 4. Moore GE, Peyton WT, et al. The clinical use 
of fluorescein in neurosurgery: the localiza-
tion of brain tumors. J Neurosurg 1948;5(4): 
392–398.
 5. Burggraaf J, Kamerlin IM, Gordon PB, et 
al. Detection of colorectal neoplasia in vivo 
in humans using an intravenously adminis-
tered fluorescent peptide targeted against 
c-Met and fluorescence colonoscopy: a 
proof of concept study. Nat Med (in press).
 6. Jaffray DA. Image-guided radiotherapy: 
from current concept to future perspectives. 
Nat Rev Clin Oncol 2012;9(12):688–699.
 7. Mariani G, Bruselli L, Kuwert T, et al. A re-
view on the clinical uses of SPECT/CT. Eur 
J Nucl Med Mol Imaging 2010;37(10):1959–
1985.
 8. Navab N, Blum T, Wang LJ, Okur A, 
Wendler T. First deployments of augmented 
reality in operating rooms. Computer 2012; 
45(7):48–55.
 9. van den Berg NS, Valdés-Olmos RA, van 
der Poel HG, van Leeuwen FW. Sentinel 
lymph node biopsy for prostate cancer: 
a hybrid approach. J Nucl Med 2013; 
54(4):493–496.
 10. Brouwer OR, van den Berg NS, Mathéron 
HM, et al. A hybrid radioactive and fluores-
cent tracer for sentinel node biopsy in pe-
nile carcinoma as a potential replacement 
for blue dye. Eur Urol 2014;65(3):600–609.
 11. Sheppard N, Willis HA, Rigg JC. Names, 
symbols, definitions and units of quantities 
in optical spectroscopy. Pure Appl Chem 
1985;57(1):105–120.
 12. Chin PT, Beekman CA, Buckle T, Joseph-
son L, van Leeuwen FW. Multispectral vi-
sualization of surgical safety-margins using 
fluorescent marker seeds. Am J Nucl Med 
Mol Imaging 2012;2(2):151–162.
 13. van der Poel HG, Buckle T, Brouwer OR, 
Valdés Olmos RA, van Leeuwen FW. In-
traoperative laparoscopic fluorescence 
guidance to the sentinel lymph node in 
prostate cancer patients: clinical proof of 
concept of an integrated functional imaging 
approach using a multimodal tracer. Eur 
Urol 2011;60(4):826–833.
 14. Garcia-Allende PB, Glatz J, Koch M, 
Ntziachristos V. Enriching the interven-
tional vision of cancer with fluorescence 
and optoacoustic imaging. J Nucl Med 
2013;54(5):664–667.
 15. Meikle SR, Kench P, Kassiou M, Banati RB. 
Small animal SPECT and its place in the 
matrix of molecular imaging technologies. 
Phys Med Biol 2005;50(22):R45–R61.
 16. Bunschoten A, Buckle T, Kuil J, et al. Target-
ed non-covalent self-assembled nanoparticles 
based on human serum albumin. Biomate-
rials 2012;33(3):867–875.
 17. Vahrmeijer AL, Frangioni JV. Seeing 
the invisible during surgery. Br J Surg 
2011;98(6):749–750.
 18. Troyan SL, Kianzad V, Gibbs-Strauss SL, et 
al. The FLARE intraoperative near-infra-
red fluorescence imaging system: a first-in-
human clinical trial in breast cancer senti-
nel lymph node mapping. Ann Surg Oncol 
2009;16(10):2943–2952.
 19. Hirche C, Engel H, Kolios L, et al. An ex-
perimental study to evaluate the Fluobeam 
800 imaging system for fluorescence-guid-
ed lymphatic imaging and sentinel node 
biopsy. Surg Innov 2013;20(5):516–523.
 20. Themelis G, Yoo JS, Soh KS, Schulz R, 
Ntziachristos V. Real-time intraoperative 
fluorescence imaging system using light-
absorption correction. J Biomed Opt 2009; 
14(6):064012.
 21. Liu Y, Akers WJ, Bauer AQ, et al. In-
traoperative detection of liver tumors 
aided by a fluorescence goggle system 
and multimodal imaging. Analyst (Lond) 
2013;138(8):2254–2257.
 22. Liu Y, Bauer AQ, Akers WJ, et al. Hands-
free, wireless goggles for near-infrared 
fluorescence and real-time image-guided 
surgery. Surgery 2011;149(5):689–698.
 23. Rodrigues EB, Costa EF, Penha FM, et al. 
The use of vital dyes in ocular surgery. 
Surv Ophthalmol 2009;54(5):576–617.
 24. Babu R, Adamson DC. Fluorescence-guid-
ed malignant glioma resections. Curr Drug 
Discov Technol 2012;9(4):256–267.
 25. Sanai N. Emerging operative strategies in 
neurosurgical oncology. Curr Opin Neurol 
2012;25(6):756–766.
 26. Chen SF, Kato Y, Oda J, et al. The applica-
tion of intraoperative near-infrared indocy-
anine green videoangiography and analysis 
Radiology: Volume 276: Number 1—July 2015 n radiology.rsna.org 27
REVIEW: Luminescence-based Approaches in  Interventional Molecular  Imaging van Leeuwen et al
of fluorescence intensity in cerebrovascular 
surgery. Surg Neurol Int 2011;2:42.
 27. Goetz M, Malek NP, Kiesslich R. Micro-
scopic imaging in endoscopy: endomicros-
copy and endocytoscopy. Nat Rev Gastro-
enterol Hepatol 2014;11(1):11–18.
 28. Zehri AH, Ramey W, Georges JF, et al. 
Neurosurgical confocal endomicroscopy: 
A review of contrast agents, confocal 
systems, and future imaging modalities. 
Surg Neurol Int 2014;5:60.
 29. Goetz M, Deris I, Vieth M, et al. Near-in-
frared confocal imaging during mini-lapa-
roscopy: a novel rigid endomicroscope with 
increased imaging plane depth. J Hepatol 
2010;53(1):84–90.
 30. KleinJan GH, van den Berg NS, Brouwer OR, 
et al. Optimisation of fluorescence guidance 
during robot-assisted laparoscopic senti-
nel node biopsy for prostate cancer. Eur 
Urol 2014;66(6):991–998.
 31. Spinelli AE, Ferdeghini M, Cavedon C, et 
al. First human Cerenkography. J Biomed 
Opt 2013;18(2):20502.
 32. Thorek DL, Riedl CC, Grimm J. Clinical 
Cerenkov luminescence imaging of (18)F-
FDG. J Nucl Med 2014;55(1):95–98.
 33. Meining A, Chen YK, Pleskow D, et al. 
Direct visualization of indeterminate pan-
creaticobiliary strictures with probe-based 
confocal laser endomicroscopy: a multi-
center experience. Gastrointest Endosc 
2011;74(5):961–968.
 34. Konda VJ, Meining A, Jamil LH, et al. 
A pilot study of in vivo identification of 
pancreatic cystic neoplasms with needle-
based confocal laser endomicroscopy un-
der endosonographic guidance. Endoscopy 
2013;45(12):1006–1013.
 35. Goetz M. Confocal laser endomicroscopy: 
applications in clinical and translational sci-
ence—a comprehensive review. ISRN Pathol 
2012;2012:387145.
 36. Smith MJ, Moore GE. Sodium tetraiodo-
phthalicfluorescein for intravenous cholecys-
tography. Radiology 1949;53(4):552–554.
 37. Alander JT, Kaartinen I, Laakso A, et al. 
A review of indocyanine green fluorescent 
imaging in surgery. Int J Biomed Imaging 
2012;2012:940585.
 38. Holm C, Dornseifer U, Sturtz G, Ninkovic 
M. Sensitivity and specificity of ICG angi-
ography in free flap reexploration. J Recon-
str Microsurg 2010;26(5):311–316.
 39. Bjurlin MA, Gan M, McClintock TR, et al. 
Near-infrared fluorescence imaging: emerg-
ing applications in robotic upper urinary 
tract surgery. Eur Urol 2014;65(4):793–801.
 40. Krane LS, Manny TB, Hemal AK. Is near 
infrared fluorescence imaging using indo-
cyanine green dye useful in robotic par-
tial nephrectomy: a prospective compar-
ative study of 94 patients. Urology 2012; 
80(1):110–116.
 41. Tobis S, Knopf JK, Silvers CR, et al. Near 
infrared fluorescence imaging after intra-
venous indocyanine green: initial clinical 
experience with open partial nephrectomy 
for renal cortical tumors. Urology 2012; 
79(4):958–964.
 42. Feindel W, Yamamoto YL, Hodge CP. In-
tracarotid fluorescein angiography: a new 
method for examination of the epicere-
bral circulation in man. Can Med Assoc J 
1967;96(1):1–7.
 43. Poellinger A, Burock S, Grosenick D, et al. 
Breast cancer: early- and late-fluorescence 
near-infrared imaging with indocyanine 
green—a preliminary study. Radiology 2011; 
258(2):409–416.
 44. Poellinger A, Persigehl T, Mahler M, et al. 
Near-infrared imaging of the breast using 
omocianine as a fluorescent dye: results of 
a placebo-controlled, clinical, multicenter 
trial. Invest Radiol 2011;46(11):697–704.
 45. Tummers QR, Verbeek FP, Schaafsma BE, 
et al. Real-time intraoperative detection of 
breast cancer using near-infrared fluores-
cence imaging and Methylene Blue. Eur J 
Surg Oncol 2014;40(7):850–858.
 46. van de Ven S, Wiethoff A, Nielsen T, et al. 
A novel fluorescent imaging agent for dif-
fuse optical tomography of the breast: first 
clinical experience in patients. Mol Imaging 
Biol 2010;12(3):343–348.
 47. Poellinger A. Near-infrared imaging of 
breast cancer using optical contrast agents. 
J Biophotonics 2012;5(11-12):815–826.
 48. Patel HP, Chadwick DR, Harrison BJ, 
Balasubramanian SP. Systematic review of 
intravenous methylene blue in parathyroid 
surgery. Br J Surg 2012;99(10):1345–1351.
 49. van der Vorst JR, Schaafsma BE, Verbeek 
FP, et al. Intraoperative near-infrared fluo-
rescence imaging of parathyroid adenomas 
with use of low-dose methylene blue. Head 
Neck 2014;36(6):853–858.
 50. Ishizawa T, Tamura S, Masuda K, et al. 
Intraoperative fluorescent cholangiography 
using indocyanine green: a biliary road 
map for safe surgery. J Am Coll Surg 2009; 
208(1):e1–e4.
 51. Sugimoto M. Recent advances in visualiza-
tion, imaging, and navigation in hepatobili-
ary and pancreatic sciences. J Hepatobili-
ary Pancreat Sci 2010;17(5):574–576.
 52. Ishizawa T, Masuda K, Urano Y, et al. 
Mechanistic background and clinical appli-
cations of indocyanine green fluorescence 
imaging of hepatocellular carcinoma. Ann 
Surg Oncol 2014;21(2):440–448.
 53. Muhi A, Ichikawa T, Motosugi U, et al. 
Diagnosis of colorectal hepatic metasta-
ses: comparison of contrast-enhanced CT, 
contrast-enhanced US, superparamagnetic 
iron oxide-enhanced MRI, and gadoxetic 
acid-enhanced MRI. J Magn Reson Imaging 
2011;34(2):326–335.
 54. Udshmadshuridze NS, Asikuri TO. In-
tra-operative imaging of the ureter with 
sodium fluorescein [in German]. Z Urol 
Nephrol 1988;81(10):635–639.
 55. Verbeek FP, van der Vorst JR, Schaaf-
sma BE, et al. Intraoperative near in-
frared fluorescence guided identification 
of the ureters using low dose methylene 
blue: a first in human experience. J Urol 
2013;190(2):574–579.
 56. Cooper SG, Maitem AN, Richman AH. 
Fluorescein labeling of lymphatic vessels 
for lymphangiography. Radiology 1988; 
167(2):559–560.
 57. Isenring G, Franzeck UK, Bollinger A. Fluo-
rescence microlymphography of the medial 
malleolus in healthy humans and in patients 
with primary lymphedema [in German]. 
Schweiz Med Wochenschr 1982;112(7): 
225–231.
 58. Kitai T, Inomoto T, Miwa M, Shikayama 
T. Fluorescence navigation with indocya-
nine green for detecting sentinel lymph 
nodes in breast cancer. Breast Cancer 
2005;12(3):211–215.
 59. Rasmussen JC, Tan IC, Marshall MV, Fife 
CE, Sevick-Muraca EM. Lymphatic imaging 
in humans with near-infrared fluorescence. 
Curr Opin Biotechnol 2009;20(1):74–82.
 60. Mariani G, Erba P, Manca G, et al. Ra-
dioguided sentinel lymph node biopsy in 
patients with malignant cutaneous mela-
noma: the nuclear medicine contribution. 
J Surg Oncol 2004;85(3):141–151.
 61. Mariani G, Erba P, Villa G, et al. Lympho-
scintigraphic and intraoperative detection 
of the sentinel lymph node in breast cancer 
patients: the nuclear medicine perspective. 
J Surg Oncol 2004;85(3):112–122.
 62. Van Den Berg NS, Buckle T, Klein-
jan GI, et al. Hybrid tracers for sentinel 
node biopsy. Q J Nucl Med Mol Imaging 
2014;58(2):193–206.
 63. Jung SY, Kim SK, Kim SW, et al. Compari-
son of sentinel lymph node biopsy guided by 
the multimodal method of indocyanine green 
fluorescence, radioisotope, and blue dye ver-
sus the radioisotope method in breast can-
cer: a randomized controlled trial. Ann Surg 
Oncol 2014;21(4):1254–1259.
28 radiology.rsna.org n Radiology: Volume 276: Number 1—July 2015
REVIEW: Luminescence-based Approaches in  Interventional Molecular  Imaging van Leeuwen et al
 64. Povoski SP, Neff RL, Mojzisik CM, et al. 
A comprehensive overview of radioguided 
surgery using gamma detection probe tech-
nology. World J Surg Oncol 2009;7:11.
 65. Rambaldi PF, Cuccurullo V, Briganti V, Man-
si L. The present and future role of (111)In 
pentetreotide in the PET era. Q J Nucl Med 
Mol Imaging 2005;49(3):225–235.
 66. Guo W, Zhang L, Ji J, Gao W, Liu J, Tong 
M. Breast cancer sentinel lymph node 
mapping using near-infrared guided indo-
cyanine green in comparison with blue dye. 
Tumour Biol 2014;35(4):3073–3078.
 67. van den Berg NS, Brouwer OR, Klop WM, 
et al. Concomitant radio- and fluorescence-
guided sentinel lymph node biopsy in 
squamous cell carcinoma of the oral cavity 
using ICG-(99m)Tc-nanocolloid. Eur J Nucl 
Med Mol Imaging 2012;39(7):1128–1136.
 68. Buckle T, Brouwer OR, Valdés Olmos RA, 
van der Poel HG, van Leeuwen FW. Rela-
tionship between intraprostatic tracer de-
posits and sentinel lymph node mapping 
in prostate cancer patients. J Nucl Med 
2012;53(7):1026–1033.
 69. Yeung JM, Maxwell-Armstrong C, Ache-
son AG. Colonic tattooing in laparoscopic 
surgery - making the mark? Colorectal Dis 
2009;11(5):527–530.
 70. Polglase AL, McLaren WJ, Skinner SA, 
Kiesslich R, Neurath MF, Delaney PM. 
A fluorescence confocal endomicroscope 
for in vivo microscopy of the upper- and 
the lower-GI tract. Gastrointest Endosc 
2005;62(5):686–695.
 71. Kiesslich R, Burg J, Vieth M, et al. Confocal 
laser endoscopy for diagnosing intraepithe-
lial neoplasias and colorectal cancer in vivo. 
Gastroenterology 2004;127(3):706–713.
 72. Goetz M, Toermer T, Vieth M, et al. Simul-
taneous confocal laser endomicroscopy and 
chromoendoscopy with topical cresyl violet. 
Gastrointest Endosc 2009;70(5):959–968.
 73. Goldenberg DM. Cancer imaging with CEA 
antibodies: historical and current perspec-
tives. Int J Biol Markers 1992;7(3):183–188.
 74. Keller R, Winde G, Terpe HJ, Foerster EC, 
Domschke W. Fluorescence endoscopy us-
ing a fluorescein-labeled monoclonal anti-
body against carcinoembryonic antigen in 
patients with colorectal carcinoma and ad-
enoma. Endoscopy 2002;34(10):801–807.
 75. van Dam GM, Themelis G, Crane LM, et 
al. Intraoperative tumor-specific fluores-
cence imaging in ovarian cancer by folate 
receptor-a targeting: first in-human re-
sults. Nat Med 2011;17(10):1315–1319.
 76. Kim EM, Park EH, Cheong SJ, et al. Char-
acterization, biodistribution and small-ani-
mal SPECT of I-125-labeled c-Met binding 
peptide in mice bearing c-Met receptor 
tyrosine kinase-positive tumor xenografts. 
Nucl Med Biol 2009;36(4):371–378.
 77. Liu J, Zuo X, Li C, et al. In vivo molecular 
imaging of epidermal growth factor recep-
tor in patients with colorectal neoplasia us-
ing confocal laser endomicroscopy. Cancer 
Lett 2013;330(2):200–207.
 78. Gaykema SB, Brouwers AH, Lub-de Hooge 
MN, et al. 89Zr-bevacizumab PET imag-
ing in primary breast cancer. J Nucl Med 
2013;54(7):1014–1018.
 79. Hsiung PL, Hardy J, Friedland S, et al. De-
tection of colonic dysplasia in vivo using a 
targeted heptapeptide and confocal micro-
endoscopy. Nat Med 2008;14(4):454–458.
 80. Sturm MB, Joshi BP, Lu S, et al. Targeted 
imaging of esophageal neoplasia with a fluo-
rescently labeled peptide: first-in-human re-
sults. Sci Transl Med 2013;5(184):84ra61.
 81. Urano Y, Kamiya M, Hino H, et al. Rapid 
and sensitive imaging of cancer cells in re-
sected human breast and lung tissues by 
novel fluorescence probes for GGT [abstr]. 
Mol Imaging Biol 2013;15(Suppl A):2-1590.
 82. Moore GE. Use of radioactive diiodofluo-
rescein in the diagnosis and localization 
of brain tumors. Science 1948;107(2787): 
569–571.
 83. Moore GE, Peyton WT, et al. The clinical 
use of sodium fluorescein and radioactive 
diiodofluorescein in the localization of tu-
mors of the central nervous system. Minn 
Med 1948;31(10):1073–1076.
 84. Brouwer OR, Buckle T, Vermeeren L, et 
al. Comparing the hybrid fluorescent-
radioactive tracer indocyanine green-
99mTc-nanocolloid with 99mTc-nanocol-
loid for sentinel node identification: a 
validation study using lymphoscintigraphy 
and SPECT/CT. J Nucl Med 2012;53(7): 
1034–1040.
 85. van den Berg NS, Brouwer OR, Schaafsma 
BE, et al. Multimodal surgical guidance 
during sentinel node biopsy for melanoma: 
combined gamma tracing and fluorescence 
imaging of the sentinel node through use 
of the hybrid tracer indocyanine green-
99mTc-nanocolloid. Radiology 2014 Dec 
17. [Epub ahead of print]
 86. Blower PJ, Kettle AG, O’Doherty MJ, Collins 
RE, Coakley AJ. 123I-methylene blue: an un-
satisfactory parathyroid imaging agent. Nucl 
Med Commun 1992;13(7):522–527.
 87. Link EM, Blower PJ, Costa DC, et al. Early 
detection of melanoma metastases with 
radioiodinated methylene blue. Eur J Nucl 
Med 1998;25(9):1322–1329.
 88. Cundiff JD, Wang YZ, Espenan G, et al. A 
phase I/II trial of 125I methylene blue for 
one-stage sentinel lymph node biopsy. Ann 
Surg 2007;245(2):290–296.
 89. Kuil J, Buckle T, Oldenburg J, et al. Hybrid 
peptide dendrimers for imaging of chemo-
kine receptor 4 (CXCR4) expression. Mol 
Pharm 2011;8(6):2444–2453.
 90. Kuil J, Buckle T, Yuan H, et al. Synthesis 
and evaluation of a bimodal CXCR4 an-
tagonistic peptide. Bioconjug Chem 2011; 
22(5):859–864.
 91. Dahners LE, Bos GD. Fluorescent tet-
racycline labeling as an aid to debride-
ment of necrotic bone in the treatment of 
chronic osteomyelitis. J Orthop Trauma 
2002;16(5):345–346.
 92. Frost HM. Tetracycline-based histological 
analysis of bone remodeling. Calcif Tissue 
Res 1969;3(3):211–237.
 93. Frost HM, Villanueva AR, Roth H, Stanisav-
ljevic S. Tetracycline bone labeling. J New 
Drugs 1961;1:206–216.
 94. Milch RA, Rall DP, Tobie JE. Bone localiza-
tion of the tetracyclines. J Natl Cancer Inst 
1957;19(1):87–93.
 95. Pautke C, Bauer F, Tischer T, et al. Fluores-
cence-guided bone resection in bisphospho-
nate-associated osteonecrosis of the jaws. J 
Oral Maxillofac Surg 2009;67(3):471–476.
 96. Pautke C, Tischer T, Neff A, Horch HH, 
Kolk A. In vivo tetracycline labeling of 
bone: an intraoperative aid in the surgical 
therapy of osteoradionecrosis of the man-
dible. Oral Surg Oral Med Oral Pathol Oral 
Radiol Endod 2006;102(6):e10–e13.
 97. Celli JP, Spring BQ, Rizvi I, et al. Imaging 
and photodynamic therapy: mechanisms, 
monitoring, and optimization. Chem Rev 
2010;110(5):2795–2838.
 98. Santos Cortes JA, Gahan J, Soloway MS. 
Photodynamic diagnosis in urology: state of 
the art. Arch Esp Urol 2011;64(1):18–31.
 99. Fotinos N, Campo MA, Popowycz F, Gurny 
R, Lange N. 5-Aminolevulinic acid deriv-
atives in photomedicine: Characteristics, 
application and perspectives. Photochem 
Photobiol 2006;82(4):994–1015.
 100. Stummer W, Pichlmeier U, Meinel T, et al. 
Fluorescence-guided surgery with 5-ami-
nolevulinic acid for resection of malignant 
glioma: a randomised controlled multicen-
tre phase III trial. Lancet Oncol 2006;7(5): 
392–401.
 101. Lerner SP, Liu H, Wu MF, Thomas YK, 
Witjes JA. Fluorescence and white light 
cystoscopy for detection of carcinoma in 
situ of the urinary bladder. Urol Oncol 
2012;30(3):285–289.
Radiology: Volume 276: Number 1—July 2015 n radiology.rsna.org 29
REVIEW: Luminescence-based Approaches in  Interventional Molecular  Imaging van Leeuwen et al
 102. Zimmermann A, Ritsch-Marte M, Kostron 
H. mTHPC-mediated photodynamic diag-
nosis of malignant brain tumors. Photo-
chem Photobiol 2001;74(4):611–616.
 103. Olivo M, Fu CY, Raghavan V, Lau WK. New 
frontier in hypericin-mediated diagnosis of 
cancer with current optical technologies. 
Ann Biomed Eng 2012;40(2):460–473.
 104. Ishizawa T, Fukushima N, Shibahara J, et 
al. Real-time identification of liver cancers 
by using indocyanine green fluorescent im-
aging. Cancer 2009;115(11):2491–2504.
 105. Azhdarinia A, Ghosh P, Ghosh S, Wil-
ganowski N, Sevick-Muraca EM. Dual-label-
ing strategies for nuclear and fluorescence 
molecular imaging: a review and analysis. 
Mol Imaging Biol 2012;14(3):261–276.
 106. Guo K, Berezin MY, Zheng J, et al. Near in-
frared-fluorescent and magnetic resonance 
imaging molecular probe with high T1 relax-
ivity for in vivo multimodal imaging. Chem 
Commun (Camb) 2010;46(21):3705–3707.
 107. Russell RW, Ffytche TJ, Sanders MD. A 
study of retinal vascular occlusion using 
fluorescein angiography. Lancet 1966;2 
(7468):821–825.
 108. Sjoback R, Nygren J, Kubista M. Absorption 
and fluorescence properties of fluorescein. 
Spectrochim Acta [A] 1995;51(6):L7–L21.
 109. Haynes WF Jr, Pittman FE. Application of 
the fluorescein string test in 32 cases of 
upper gastrointestinal hemorrhage. Pre-
liminary report. Gastroenterology 1960; 
38:690–697.
 110. Isak SJ, Eyring EM. Fluorescence quantum 
yield of cresyl violet in methanol and water 
as a function of concentration. J Phys Chem 
1992;96(4):1738–1742.
 111. Tardivo JP, Del Giglio A, de Oliveira CS, et 
al. Methylene blue in photodynamic ther-
apy: From basic mechanisms to clinical ap-
plications. Photodiagn Photodyn Ther 2005; 
2(3):175–191.
 112. Tannous Z, Al-Arashi M, Shah S, Yaro-
slavsky AN. Delineating melanoma using 
multimodal polarized light imaging. Lasers 
Surg Med 2009;41(1):10–16.
 113. Holm C, Tegeler J, Mayr M, Becker A, 
Pfeiffer UJ, Mühlbauer W. Monitoring free 
flaps using laser-induced fluorescence of in-
docyanine green: a preliminary experience. 
Microsurgery 2002;22(7):278–287.
 114. Yuan B, Chen N, Zhu Q. Emission and 
absorption properties of indocyanine 
green in Intralipid solution. J Biomed Opt 
2004;9(3):497–503.
 115. Guyer DR, Yannuzzi LA, Slakter JS, et al. 
Classification of choroidal neovasculariza-
tion by digital indocyanine green videoan-
giography. Ophthalmology 1996;103(12): 
2054–2060.
 116. Unno N, Inuzuka K, Suzuki M, et al. Pre-
liminary experience with a novel fluores-
cence lymphography using indocyanine 
green in patients with secondary lymph-
edema. J Vasc Surg 2007;45(5):1016–1021.
 117. Lee Z, Simhan J, Parker DC, et al. Novel 
use of indocyanine green for intraopera-
tive, real-time localization of ureteral ste-
nosis during robot-assisted ureteroureter-
ostomy. Urology 2013;82(3):729–733.
 118. Ishizawa T, Zuker NB, Kokudo N, Gayet 
B. Positive and negative staining of hepatic 
segments by use of fluorescent imaging 
techniques during laparoscopic hepatec-
tomy. Arch Surg 2012;147(4):393–394.
 119. Folli S, Wagnières G, Pèlegrin A, et al. Im-
munophotodiagnosis of colon carcinomas 
in patients injected with fluoresceinated 
chimeric antibodies against carcinoem-
bryonic antigen. Proc Natl Acad Sci U S A 
1992;89(17):7973–7977.
 120. Mujumdar RB, Ernst LA, Mujumdar SR, 
Lewis CJ, Waggoner AS. Cyanine dye label-
ing reagents: sulfoindocyanine succinimidyl 
esters. Bioconjug Chem 1993;4(2):105–111.
 121. Sakabe M, Asanuma D, Kamiya M, et al. 
Rational design of highly sensitive fluores-
cence probes for protease and glycosidase 
based on precisely controlled spirocycliza-
tion. J Am Chem Soc 2013;135(1):409–414.
 122. Li Z, Zuo XL, Li CQ, et al. In vivo molec-
ular imaging of gastric cancer by targeting 
MG7 antigen with confocal laser endomi-
croscopy. Endoscopy 2013;45(2):79–85.
 123. h t tp : / /c l in i ca l t r i a l s . gov/c t2/show/
NCT01508572.
 124. Tanaka E, Choi HS, Humblet V, Ohnishi 
S, Laurence RG, Frangioni JV. Real-time 
intraoperative assessment of the extrahe-
patic bile ducts in rats and pigs using invis-
ible near-infrared fluorescent light. Surgery 
2008;144(1):39–48.
 125. Ohnishi S, Garfein ES, Karp SJ, Fran-
gioni JV. Radiolabeled and near-infrared 
fluorescent fibrinogen derivatives create a 
system for the identification and repair of 
obscure gastrointestinal bleeding. Surgery 
2006;140(5):785–792.
 126. Pautke C, Bauer F, Otto S, et al. Fluores-
cence-guided bone resection in bisphospho-
nate-related osteonecrosis of the jaws: first 
clinical results of a prospective pilot study. 
J Oral Maxillofac Surg 2011;69(1):84–91.
 127. Carlotti B, Fuoco D, Elisei F. Fast and ul-
trafast spectroscopic investigation of tetra-
cycline derivatives in organic and aqueous 
media. Phys Chem Chem Phys 2010;12(48): 
15580–15591.
 128. Ayala AG, Murray JA, Erling MA, Raymond 
AK. Osteoid-osteoma: intraoperative tetra-
cycline-fluorescence demonstration of the 
nidus. J Bone Joint Surg Am 1986;68(5): 
747–751.
 129. Yaroslavsky AN, Salomatina EV, Neel V, 
Anderson R, Flotte T. Fluorescence po-
larization of tetracycline derivatives as a 
technique for mapping nonmelanoma skin 
cancers. J Biomed Opt 2007;12(1):014005.
 130. Lozovaya GI, Masinovsky Z, Sivash AA. 
Protoporphyrin-Ix as a possible ancient 
photosensitizer - spectral and photochem-
ical studies. Orig Life Evol Biosph 1990; 
20(3-4):321–330.
 131. Niziolek M, Korytowski W, Girotti AW. Self-
sensitized photodegradation of membrane-
bound protoporphyrin mediated by chain 
lipid peroxidation: inhibition by nitric ox-
ide with sustained singlet oxygen damage. 
Photochem Photobiol 2005;81(2):299–305.
 132. Yamazaki T, Ohta N, Yamazaki I, Song 
PS. Excited-state properties of hypericin: 
electronic spectra and fluorescence decay 
kinetics. J Phys Chem 1993;97(30):7870–
7875.
 133. García-Díaz M, Sánchez-García D, Soriano 
J, et al. Temocene: the porphycene ana-
logue of temoporfin (Foscan®). Med Chem 
Commun 2011;2(7):616–619.
 134. Xie H, Liu H, Svenmarker P, et al. Drug 
quantification in turbid media by fluo-
rescence imaging combined with light-
absorption correction using white Monte 
Carlo simulations. J Biomed Opt 2011; 
16(6):066002.
 135. Ishizawa T, Masuda K, Satou S, et al. Indo-
cyanine green-fluorescent imaging for iden-
tifying hepatocellular carcinoma during 
liver resection. From: Proceedings of the 
2010 World Molecular Imaging Congress, 
Kyoto, Japan. Mol Imaging Biol 2010;12(2 
Suppl):500–1636.
 136. Lapini A, Minervini A, Masala A, et al. A 
comparison of hexaminolevulinate (Hex-
vix(®)) fluorescence cystoscopy and white-
light cystoscopy for detection of bladder 
cancer: results of the HeRo observational 
study. Surg Endosc 2012;26(12):3634–3641.
